Survodutide Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Survodutide evidence and protocol review

Metabolic Research peptide Lyophilized verified

Also known as: BI 456906

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

5 mg, 10 mg, 20 mg

Calculator

Preset available

Storage

Investigational compound - no FDA label. Use source COA / vendor storage guidance and verify independently before recording.

Solubility

Aqueous solution for SC injection; acylated peptide

Catalog Description

Survodutide is a glucagon/GLP-1 receptor dual agonist. The Phase 3 SYNCHRONIZE-1 trial (NEJM, presented at ADA 2026; N=725) reported up to 16.6% mean weight loss at 76 weeks versus 3.2% placebo, with up to 85.1% of participants achieving >=5% weight reduction. Pre-specified body-composition analysis reported up to 34% visceral fat reduction and up to 63.1% liver fat reduction, with lean-mass loss limited to <=10.8% of total tissue-mass change at the highest dose. Not yet FDA-approved as of 2026.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Supports once-weekly dosing in Phase 3 trials (exact published half-life not confirmed by two independent sources; do not state without further verification)

Onset

Progressive over 76-week trial duration

Administration Routes (Research)

Reported Research Effects

Weight loss via dual glucagon/GLP-1 mechanism
Substantial visceral and liver fat reduction in trial body-composition sub-analysis
Relatively preserved lean mass vs. total weight lost

Reported Research Side Effects

Human safety, pharmacokinetics, and interaction data are incomplete

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

0.6 mg target arm: weeks 1-2 0.3 mg, weeks 3-46 0.6 mg [SC; 46-week Phase 2 regimen; Weekly]Source: EU trial results 2020-002479-37
2.4 mg target arm: weeks 1-2 0.3 mg, weeks 3-4 0.6 mg, weeks 5-6 0.9 mg, weeks 7-10 1.2 mg, weeks 11-14 1.8 mg, weeks 15-20 2.4 mg, weeks 21-46 2.4 mg maintenance [SC; 20-week escalation then 26-week maintenance; Weekly]Source: EU trial results 2020-002479-37
3.6 mg target arm: weeks 1-2 0.3 mg, weeks 3-4 0.6 mg, weeks 5-6 0.9 mg, weeks 7-10 1.2 mg, weeks 11-12 1.8 mg, weeks 13-14 2.4 mg, weeks 15-16 3.0 mg, weeks 17-20 3.6 mg, weeks 21-46 3.6 mg maintenance [SC; 20-week escalation then 26-week maintenance; Weekly]Source: EU trial results 2020-002479-37
4.8 mg target arm: weeks 1-2 0.3 mg, weeks 3-4 0.6 mg, weeks 5-6 0.9 mg, weeks 7-8 1.2 mg, weeks 9-10 1.8 mg, weeks 11-12 2.4 mg, weeks 13-14 3.3 mg, weeks 15-16 4.2 mg, weeks 17-20 4.8 mg, weeks 21-46 4.8 mg maintenance [SC; 20-week escalation then 26-week maintenance; Weekly]Source: EU trial results 2020-002479-37

Research Notes

Survodutide remains investigational. The Phase 2 obesity study used different arm-specific 20-week escalations and permitted tolerability-driven adjustment during the flexible phase; one generic ladder would be inaccurate.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Survodutide Phase 2 EU trial results with arm-specific escalation — EU Clinical Trials Register
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002479-37/results

Survodutide Phase 2 obesity trial — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/38330987/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Where to Source Survodutide

The following are third-party vendor links for this compound, provided for reference only. Some may be affiliate links, and prices/coupons are entered manually and may not always reflect the vendor's current listing. No affiliation, endorsement, or product claim is implied. Verify price, coupon validity, and product specifications directly on the vendor's site before purchase.

COA verified

Survodutide

G1P-5 SV 5mg G1P-5 SV 5mg — Full 10-Vial Kit

Hacker Peptides

In stock

COA Batch A2SV50925

$69.00 $40.25

-41.67%

Shop ↗

Third-party links — not affiliated with this site. Not a recommendation for human use. Research compounds are for laboratory and educational use only.

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.